RT Journal Article
SR Electronic
T1 In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 1624
OP 1631
DO 10.1124/dmd.106.009746
VO 34
IS 9
A1 Emma Boström
A1 Ulrika S. H. Simonsson
A1 Margareta Hammarlund-Udenaes
YR 2006
UL http://dmd.aspetjournals.org/content/34/9/1624.abstract
AB The blood-brain barrier (BBB) transport of oxycodone was studied in rats. Microdialysis probes were inserted into the striatum and vena jugularis. Ten animals were given a bolus dose followed by a 120-min constant rate infusion to study the steady-state concepts of oxycodone BBB equilibration. Another 10 animals were given a 60-min constant rate infusion to study the rate of equilibration across the BBB. Oxycodone-D3 was used as a calibrator for the microdialysis experiments. The samples were analyzed with a liquid chromatography-tandem mass spectrometry method and a population pharmacokinetic model was used to simultaneously fit all the data using NONMEM. A two-compartment model which allowed for a delay between the venous and arterial compartments best described the pharmacokinetics for oxycodone in blood and plasma, whereas a one-compartment model was sufficient to describe the pharmacokinetics in the brain. The BBB transport of oxycodone was parameterized as CLin and Kp,uu. CLin describes the clearance of oxycodone across the BBB into the brain, whereas Kp,uu describes the extent of drug equilibration across the BBB. CLin across the BBB was estimated to 1910 μl/min · g brain. Kp,uu was estimated to 3.0, meaning that the unbound concentration of oxycodone in brain was 3 times higher than in blood, which is an indication of active influx of oxycodone at the BBB. This is the first evidence of an opioid having an unbound steady-state concentration in brain that is higher than unity, which can explain potency discrepancies between oxycodone and other opioids. The American Society for Pharmacology and Experimental Therapeutics